Cancer-associated_cachexia

Olanzapine for Anorexia in Patients With Incurable Cancer and Cachexia (OlAnCa): A Double-Blind, Placebo-Controlled, Randomized Clinical Trial.

Pharmacologic options for managing anorexia in cancer cachexia are limited. This trial aimed to evaluate the efficacy of olanzapine in alleviating anorexia in patients with incurable cancer and cachexia. This double-blind, placebo-controlled, randomized trial included adult patients with incurable cancer...

๐Ÿ—“๏ธ 2025-07-30
๐Ÿ“ฐ Publication: Journal Of The National Comprehensive Cancer Network
Read MoreOlanzapine for Anorexia in Patients With Incurable Cancer and Cachexia (OlAnCa): A Double-Blind, Placebo-Controlled, Randomized Clinical Trial.

Functional liver genomics identifies hepatokines promoting wasting in cancer cachexia.

In cancer cachexia, the presence of a tumor triggers systemic metabolic disruption that leads to involuntary body weight loss and accelerated mortality in affected patients. Here, we conducted transcriptomic and epigenomic profiling of the liver in various weight-stable cancer and...

๐Ÿ—“๏ธ 2025-07-18
๐Ÿ“ฐ Publication: Cell
Read MoreFunctional liver genomics identifies hepatokines promoting wasting in cancer cachexia.

Thymic Microenvironment Remodeling in Cancer Cachexia as a Determinant of Checkpoint Inhibitor Efficacy and Toxicity.

The discovery of immune checkpoints links autoimmunity and cancer, with thymus atrophy reportedly causing autoimmune multiorgan inflammation. The impact of cancer cachexia on thymic involution and its clinical significance remains unclear. This study aimed to investigate this effect and its...

๐Ÿ—“๏ธ 2025-08-01
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreThymic Microenvironment Remodeling in Cancer Cachexia as a Determinant of Checkpoint Inhibitor Efficacy and Toxicity.

High expression of the cachexia-related protein Fn14 in esophageal squamous cell carcinoma correlates with poor chemotherapy response and anti-Fn14 therapy decreases chemotherapeutic resistance.

In cancer cachexia, cytokine release by tumours causes weight loss, decreased therapeutic efficacy, and worsened prognosis. Tumour necrosis factor-like weak inducer of apoptosis (TWEAK) and fibroblast inducible factor 14 (Fn14) are cancer cachexia-related proteins; however, their expression in oesophageal squamous...

๐Ÿ—“๏ธ 2025-07-15
๐Ÿ“ฐ Publication: British Journal Of Cancer
Read MoreHigh expression of the cachexia-related protein Fn14 in esophageal squamous cell carcinoma correlates with poor chemotherapy response and anti-Fn14 therapy decreases chemotherapeutic resistance.

GDF15: from biomarker to target in cancer cachexia.

Most patients with advanced cancer suffer from cachexia, a complex metabolic disorder characterized by unintentional body weight loss that diminishes their quality of life and reduces the effectiveness of therapies. Currently, effective treatments for cachexia remain elusive. Growth differentiation factor...

๐Ÿ—“๏ธ 2025-07-09
๐Ÿ“ฐ Publication: Trends In Cancer
Read MoreGDF15: from biomarker to target in cancer cachexia.

Scutellarein attenuates cancer cachexia-induced muscle atrophy via targeted inhibition of the JAK/STAT pathway.

Cancer cachexia is a multifaceted metabolic syndrome characterized by severe loss of skeletal muscle and adipose tissue, diminishing both quality of life and survival in cancer patients. Despite its prevalence, effective treatments for cancer cachexia remain limited. The JAK/STAT signaling...

๐Ÿ—“๏ธ 2025-07-03
๐Ÿ“ฐ Publication: Journal Of Advanced Research
Read MoreScutellarein attenuates cancer cachexia-induced muscle atrophy via targeted inhibition of the JAK/STAT pathway.

Pancreatic Cancer-Derived Extracellular Vesicles Enriched with miR-223-5p Promote Skeletal Muscle Wasting Associated with Cachexia.

Pancreatic ductal adenocarcinoma (PDAC) with cachexia-related muscle wasting as the main manifestation is associated with poor overall survival. Extracellular vesicles (EVs) are key mediators of inter-organ communication. Here, EVs and EV-microRNAs (miRNAs) are identified as mediate PDAC-skeletal muscle communication. EVs...

๐Ÿ—“๏ธ 2025-07-02
Read MorePancreatic Cancer-Derived Extracellular Vesicles Enriched with miR-223-5p Promote Skeletal Muscle Wasting Associated with Cachexia.

Effect of Cancer Cachexia on the Efficacy and Treatment Delivery of Chemotherapy in Older Patients With Advanced Small Cell Lung Cancer.

Cachexia is a syndrome in patients with cancer that reduces life quality and prognosis, characterized by severe weight loss, muscle atrophy, and anorexia. How cachexia adversely affects older patients with small cell lung cancer (SCLC) remains uncertain. This study aimed...

๐Ÿ—“๏ธ 2025-06-01
๐Ÿ“ฐ Publication: Thoracic Cancer
Read MoreEffect of Cancer Cachexia on the Efficacy and Treatment Delivery of Chemotherapy in Older Patients With Advanced Small Cell Lung Cancer.

Exercise and Nutrition Therapy in a Patient With Glottic Cancer Cachexia Undergoing Chemoradiotherapy: A Case Report.

Cancer cachexia is a common complication in patients undergoing chemoradiotherapy (CRT) for head and neck cancer (HNC), leading to skeletal muscle loss, decreased physical function, and poor prognosis. Cachexia is frequently observed in patients with HNC, yet evidence supporting effective...

๐Ÿ—“๏ธ 2025-05-20
Read MoreExercise and Nutrition Therapy in a Patient With Glottic Cancer Cachexia Undergoing Chemoradiotherapy: A Case Report.

Desensitizing Effect of Intra-Tumoral GDF-15 on Immunotherapy in Patients With Advanced Non-Small Cellย Lung Cancer.

Serum growth/differentiation factor 15 (GDF-15) suppresses anti-tumor immunity and predicts prognosis in several malignancies. Elevated GDF-15 levels are linked to cancer cachexia, characterized by weight loss and systemic inflammation, adversely affecting patient outcomes and therapy response. However, serum GDF-15 is...

๐Ÿ—“๏ธ 2025-05-01
๐Ÿ“ฐ Publication: Thoracic Cancer
Read MoreDesensitizing Effect of Intra-Tumoral GDF-15 on Immunotherapy in Patients With Advanced Non-Small Cellย Lung Cancer.

The potential of TAOK1 as a new therapeutic target for the treatment of cancer cachexia-associated muscle atrophy.

Cancer cachexia, a multifactorial metabolic syndrome impacts 50-80% cancer patients, is mainly characterized by skeletal muscle atrophy. In this study, we demonstrated that the thousand-and-one amino acid kinase 1 (TAOK1) was activated in both C2C12 myotubes treated with simulated cancer...

๐Ÿ—“๏ธ 2025-05-06
๐Ÿ“ฐ Publication: Pharmacological Research
Read MoreThe potential of TAOK1 as a new therapeutic target for the treatment of cancer cachexia-associated muscle atrophy.

Stool Microbiome Features and Weight Change Response to Treatment for cancer cachexia.

Cancer cachexia is characterised by significant weight loss and muscle wasting that adversely affects patient outcomes. Nutritional interventions in cancer cachexia leads to improved outcomes, including improved weight change. However, there are wide variations in weight response to dietary interventions....

๐Ÿ—“๏ธ 2025-06-01
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreStool Microbiome Features and Weight Change Response to Treatment for cancer cachexia.

Hepatic gluconeogenesis and PDK3 upregulation drive cancer cachexia in flies and mice.

Cachexia, a severe wasting syndrome characterized by tumour-induced metabolic dysregulation, is a leading cause of death in people with cancer, yet its underlying mechanisms remain poorly understood. Here we show that a longitudinal full-body single-nuclei-resolution transcriptome analysis in a Drosophila...

๐Ÿ—“๏ธ 2025-04-16
Read MoreHepatic gluconeogenesis and PDK3 upregulation drive cancer cachexia in flies and mice.

Subscribe to the SCWD Newsletter

Stay Informed with the Latest Updates and Exclusive Insights!